Incentivizing Drug Development in Serious Mental Illness

Hannah Geils; Abigail Riley; Tara A Lavelle

doi:10.1016/j.clinthera.2022.08.002

Incentivizing Drug Development in Serious Mental Illness

Clin Ther. 2022 Sep;44(9):1258-1267. doi: 10.1016/j.clinthera.2022.08.002. Epub 2022 Aug 31.

Authors

Hannah Geils¹, Abigail Riley², Tara A Lavelle²

Affiliations

¹ Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts. Electronic address: geils@bu.edu.
² Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.

PMID: 36055863
DOI: 10.1016/j.clinthera.2022.08.002

Abstract

Serious mental illness (SMI) imposes a significant burden on individuals and society. Individuals living with SMI have worse expected health, education, and career outcomes during their lifetime. Although treatments exist, pharmaceutical innovation in this area has lagged many other disease areas, despite an important need for new treatments. This report describes barriers that have hindered innovation and the development of new drugs for SMI, including science and research, regulatory, and health system barriers. To address these barriers, this report presents policies that may incentivize investment in this area.

Keywords: Healthcare policy; Incentive; Pharmaceutical innovation; Pharmaceutical research; Regulation; Serious mental illness.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Drug Development
Humans
Mental Disorders* / drug therapy
Motivation
Pharmaceutical Preparations

Substances

Pharmaceutical Preparations